NICE Recommends Kadcyla, Kyprolis and Rejects Besponsa Coverage

International Pharmaceutical Regulatory Monitor
A A
The U.K. is planning to move Roche’s Kadcyla (trastuzumab emtansine) into the NHS’s routine funding programs later this summer, following guidance from the National Institute for Health and Care Excellence and an agreement from Roche to lower the cost of the breast cancer treatment.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor